Clinical Guidelines

Beyond Morphology and IHC

Can molecular profiling and AI help uncover tumor origin and actionable biomarkers?

Share

Molecular testing is emerging as a crucial tool in the diagnosis and management of cancers of unknown primary (CUP) and other ambiguously classified tumors. Traditional pathology methods like morphology and immunohistochemistry often fail to provide definitive classifications, especially in cases with limited tissue samples or conflicting clinical contexts. By utilizing molecular techniques, clinicians can uncover actionable biomarkers, facilitating targeted treatment decisions and improving patient outcomes. Lead researchers Jie-Fu Chen and JinJuan Yao highlight the importance of integrating molecular insights into routine diagnostics, especially as AI tools continue to evolve.

Original Source(s)

Beyond Morphology and IHC

  • by Jessica Allerton

  • March 16, 2026

Related Content

Vitamin D Deficiency and Bone Disease

Review finds limited evidence that common vitamin D deficiency cutoffs consistently reflect bone disease risk in community dwellers

Value-based Healthcare: The Vision

Founding members of the Santa Fe Project discuss the role of pathology in improving population-level health

Can Apps Improve Urgent Care Diagnoses?

Researchers assess a digital symptom history app in urgent care, comparing physician diagnoses with expert review and follow-up care.